Alvotech (NASDAQ: ALVO) Q1 2026 results and FDA review of key biosimilars

Rhea-AI Filing Summary

Alvotech reported Q1 2026 total revenues of $105.9 million, down from $132.8 million a year earlier, with Adjusted EBITDA of $24.4 million and a 57% gross margin. Statutory profit was $1.0 million, helped by finance income, but operating cash flow was a $60.4 million outflow, reducing cash to $63.8 million as of March 31, 2026.

Debt remains high with outstanding borrowings of about $1.31 billion. Management still guides for 2026 revenues of $650–$700 million and Adjusted EBITDA of $180–$220 million, assuming growing biosimilar uptake and new launches. The company concluded it remains a going concern but may need additional financing if cash generation lags.

Strategically, regulators accepted a Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio, with an FDA review period of up to six months. The EMA has also validated a marketing application covering AVT16 and AVT80, and Alvotech expanded commercial agreements and advanced multiple pipeline programs, including Eylea HD and Entyvio biosimilar candidates.

Positive

• Regulatory and pipeline progress: FDA accepted the BLA for AVT16, a proposed interchangeable Entyvio biosimilar, and the EMA validated a marketing application for AVT16 and AVT80, adding potential future revenue streams alongside new commercial agreements and positive pivotal data for key biosimilar candidates.

Negative

• Revenue decline and cash burn: Q1 2026 revenues fell to $105.9m from $132.8m, while operating activities used $60.4m of cash, leaving $63.8m of cash against about $1.31bn of borrowings and reinforcing dependence on successful launches and potential future financing.

Insights

Biotech equity analyst

Pipeline momentum offsets softer Q1 revenues but cash burn and leverage stay elevated.

Alvotech’s Q1 2026 revenues were $105.9m versus $132.8m a year earlier, mainly reflecting production slowdowns during facility improvements. Adjusted EBITDA reached $24.4m on a 57% gross margin, showing the underlying business can generate operating profit despite lower volume.

However, operating cash outflow of $60.4m and cash of only $63.8m against total borrowings of about $1.31bn highlight balance sheet pressure. Management still expects 2026 revenues of $650–$700m and Adjusted EBITDA of $180–$220m, but execution on launches and milestone collections will be critical.

On the strategic side, FDA acceptance of the AVT16 BLA and EMA validation for AVT16/AVT80, plus settlement and commercialization agreements for AVT06 and other assets, broaden medium‑term revenue options. Actual impact will depend on timely regulatory approvals, manufacturing reliability and commercialization by partners such as Teva and Advanz.

Key Figures

Total revenues: $105.9m Adjusted EBITDA: $24.4m Profit for the period: $1.0m +5 more

8 metrics

Total revenues $105.9m Three months ended 31 March 2026 vs $132.8m in 2025

Adjusted EBITDA $24.4m Q1 2026, with gross margin of 57%

Profit for the period $1.0m Three months ended 31 March 2026

Net cash from operating activities -$60.4m Operating cash flow Q1 2026

Cash and cash equivalents $63.8m As of 31 March 2026

Total borrowings $1,309.6m Outstanding borrowings net as of 31 March 2026

2026 revenue outlook $650–$700m Management guidance for total revenues in 2026

2026 Adjusted EBITDA outlook $180–$220m Management guidance for Adjusted EBITDA in 2026

Key Terms

Biologics License Application, interchangeable biosimilar, Adjusted EBITDA, contract assets, +2 more

6 terms

Biologics License Application regulatory

"its Biologics License Application (“BLA”) for AVT16…has been accepted for review"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

interchangeable biosimilar medical

"AVT16, a proposed interchangeable biosimilar to Entyvio"

An interchangeable biosimilar is a version of a complex biological medicine that regulators have judged to be so similar to the original product that it can be substituted at the pharmacy without a new prescription. For investors, interchangeability matters because it usually speeds patient access and enables automatic substitution, which can sharply increase market share for the cheaper product and put pricing pressure on the original drug, affecting future revenues and margins.

Adjusted EBITDA financial

"Adjusted EBITDA1 was $24.4m with Gross Margin of 57%"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

contract assets financial

"As of 31 March 2026, $130.0 million and $58.4 million are recorded as non-current contract assets and current contract assets"

Contract assets are amounts a company has earned by doing work or delivering goods under a customer agreement but has not yet billed or collected because certain contract conditions remain. Think of it as completed work sitting in a company’s toolbox waiting for an invoice trigger. For investors, growing contract assets signal future cash and revenue potential but also raise questions about timing, cash collection risk and the real strength of reported sales.

Predecessor Earn Out Shares financial

"The Predecessor Earn Out Shares had a fair value of $1.8 million"

going concern financial

"management concluded that the Group has the ability to continue as a going concern for at least one year"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-41421

Alvotech

(Translation of registrant's name into English)

9, Rue de Bitbourg,

L-1273 Luxembourg,

Grand Duchy of Luxembourg

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

Incorporation by Reference

This Report on Form 6-K (this “Report”) of Alvotech (the “Company”), including Exhibit 99.3 and excluding Exhibits 99.1 and 99.2 attached hereto, shall be deemed to be incorporated by reference into the Company’s registration statements on Forms F-3 (File Nos. 333-266136, 333-273262, 333-275111 and 333-281684), the Company’s registration statement on Form F-3ASR (File No. 333-289006), and the Company’s registration statement on Form S-8 (File No. 333-266881) and to be a part thereof from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Exhibits 99.1 and 99.2 to this Report are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall the be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

FDA Acceptance of BLA for AV16

On June 8, 2026, the Company issued a press release announcing that its Biologics License Application (“BLA”) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration, has been accepted for review by the U.S. Food and Drug Administration. The Company expects a review period of up to six months from the date of submission of the BLA. Under a partnership with Teva Pharmaceutical Industries Ltd. (“Teva”), the Company is responsible for development and manufacturing of AVT16, while Teva is responsible for commercialization. A copy of the press release is furnished herewith as Exhibit 99.1.

Q1 2026 Financial Results

The Company has released a copy of its unaudited condensed consolidated interim financial statements, and the accompanying notes thereto, for the three months ended March 31, 2026 filed herewith as Exhibit 99.3. A copy of the press release of the Company published on May 6, 2026 relating to its financial results of three months ended March 31, 2026 is being furnished as Exhibit 99.2. 

Forward Looking Statements

Statements contained in this Report regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, without limitation, statements about the timing and likelihood of regulatory filings and approvals for AVT16, including potential approval of AVT16 by the U.S. Food and Drug Administration. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expects,” “plans,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks and uncertainties associated with the Company’s business in general, the impact of macroeconomic and geopolitical events and the other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this Report speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated June 8, 2026
99.2		Press Release dated May 6, 2026
99.3		Alvotech Unaudited Condensed Consolidated Interim Financial Statements for First Three Months of 2026 with notes

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Alvotech
	(Registrant)
Date: June 8, 2026	/s/ Tanya Zharov
	Tanya Zharov
	General Counsel

EXHIBIT 99.1

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio^® (vedolizumab) lyophilized vial for intravenous administration.

Under a partnership with Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), Alvotech is responsible for development and manufacturing of AVT16, while Teva is responsible for commercialization.

“FDA acceptance of the BLA for AVT16 is another important step in advancing our mission to increase access to biologic medicines for patients worldwide,” said Joseph McClellan, Chief Operating Officer of Alvotech. “Our proposed interchangeable biosimilar to Entyvio builds on our experience in immunology and reflects the strength of our fully integrated development and manufacturing platform.”

Entyvio is a biologic medicine approved for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease.

AVT16 is among Alvotech’s disclosed biosimilar candidates in immunology and form part of the company’s broader pipeline of biosimilar candidates aimed at expanding access to biologic medicines in major therapeutic areas.

The BLA submission is supported by a comprehensive data package, including analytical, pharmacokinetic, and immunogenicity data generated to support the demonstration of biosimilarity between AVT16 and the reference product.

AVT16 has been submitted as a proposed interchangeable biosimilar. In the United States, an interchangeable biosimilar may be substituted for the reference product at the pharmacy without the intervention of the prescriber, subject to applicable laws. If approved, AVT16 would add to the range of biosimilar options available to patients and healthcare providers in the United States.

In February 2026, Alvotech announced positive results from a pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio for subcutaneous administration. The randomized, double-blind, single-dose, parallel-group, three-arm study compared AVT80 to Entyvio in healthy adult participants and met all its primary endpoints. Based on regulatory advice, the clinical study is considered pivotal to support the demonstration of clinical similarity for both AVT16 and AVT80.

About AVT16

AVT16 is a proposed interchangeable biosimilar candidate to Entyvio^® (vedolizumab), a humanized monoclonal antibody. AVT16 is being developed as a lyophilized vial for intravenous administration. In the European Union, the European Medicines Agency has validated a Marketing Authorization Application covering both AVT16 (lyophilized vial) and AVT80 (pre-filled syringe and auto-injector). AVT16 and AVT80 are investigational products and have not received regulatory approval in any markets.

Biosimilarity and interchangeability have not been established by regulatory authorities and are not claimed.

About Entyvio^®

Entyvio^® (vedolizumab) is an integrin receptor antagonist indicated for the treatment of adults with moderately to severely active ulcerative colitis and Crohn’s disease. Vedolizumab targets and binds specifically to the alpha-4-beta-7 integrin, which is involved in the migration of certain white blood cells into gastrointestinal tissue.

Use of trademarks

Entyvio^® is a registered trademark of Millennium Pharmaceuticals, Inc. The use of this trademark is solely for the purpose of identifying the reference product. Alvotech and Teva do not claim any rights to the trademark.

For further information, contact:

Media
Benedikt Stefansson
Sarah MacLeod
alvotech.media@alvotech.com

Investors
Dr. Balaji V Prasad
Benedikt Stefansson
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in biosimilars by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram and YouTube.

Alvotech Forward Looking Statements
Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

EXHIBIT 99.2

Alvotech Q1 2026 Financial Results

REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) --

Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)

Financial Highlights 

A supplemental long‑form earnings release providing additional operational details and business update for Q1 2026 is available at: https://investors.alvotech.com/earnings-calendar under “Q1 2026 Earnings Call”. The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release.

Q1 2026 Highlights

• Total revenues¹ were $105.9m compared to $132.8m in the same period last year
• Adjusted EBITDA¹ was $24.4m with Gross Margin of 57%
  
  Post-period end:
  
• Submitted a Marketing Authorization Application to the European Medicines Agency for AVT16 and AVT80, proposed biosimilars to Entyvio^® (vedolizumab)
• Commenced a pivotal efficacy and safety study for AVT29 for Eylea HD^® in support of a submission in the US in 2028
• Entered into a strategic manufacturing agreement with FUJIFILM Biotechnologies, establishing a U.S.-based second source of commercial supply
  
  

Comments by Lisa Graver, CEO:

“During the quarter, we continued to execute across multiple strategic priorities, including progressing the FDA resubmission process, expanding our commercial portfolio, advancing high-value pipeline programmes, and further strengthening our manufacturing platform.

“In recent months, we have implemented several important improvements across our quality systems and operations. Importantly, we have deliberately taken additional time to substantially de-risk future operational and regulatory disruption and to ensure that when we resubmit to the FDA, we do so with a package that fully addresses the agency’s requirements and supports the long-term growth and value of the company.

“Both revenues and EBITDA were impacted in the quarter by a slowdown in production related to these facility improvements. We expect a recovery in product revenues as normal operations resume.

“Commercially, we continue to see strong underlying demand for biosimilars across our marketed portfolio, including continued momentum for our Humira biosimilar in the U.S. market.

“At the same time, we advanced several important pipeline programmes, including a marketing submission to the European Medicines Agency for our proposed biosimilar to Entyvio, and continued progress with our programme for high-dose Eylea, where the first patients have now been enrolled in a pivotal clinical study.

“In addition, we have today announced a strategic manufacturing agreement with FUJIFILM Biotechnologies covering multiple products in our portfolio. This is an important step to further strengthen and diversify our manufacturing network that supports the next phase of commercial launches.

“We remain highly focused on resubmitting our BLAs pending approval with the U.S. FDA in the second quarter. Actions taken since last year strengthen not only the packages for resubmission but also our operational platform more broadly, supporting future pipeline execution. With these improvements, we believe the company is well positioned for its next phase of growth.”

Outlook for 2026

Management anticipates total revenues to be in the range of $650-$700 million and adjusted EBITDA to be in the range of $180-220 million in 2026. The lower end of the revenue range assumes no revenues from new launches into the U.S. market in 2026.

Invitation to Q1 2026 management presentation:

Join us to listen to the live audio webcast at 8:00 AM EST (12:00 GMT, 13:00 CET) on Thursday, May 7, 2026.

The audio webcast will be accessible via the following link:
https://edge.media-server.com/mmc/p/ppckxq33

To participate via telephone in the Q&A session, please register using this link to obtain your PIN:
https://register-conf.media-server.com/register/BIdfe56c21c8d448efb09f3c30405bb00d

Presentation slides for the webcast and other materials are available under “Q1 2026 Earnings Call” at: https://investors.alvotech.com/earnings-calendar

For further information, please contact:

Media – alvotech.media@alvotech.com
Benedikt Stefansson
Sarah MacLeod

Investors - alvotech.ir@alvotech.com
Dr. Balaji V Prasad
Benedikt Stefansson

The information was submitted for publication through the agency of the contact persons.

Financial calendar:

Annual or interim results will be released on the dates specified below, after the close of U.S. markets. An earnings call is held on the following day, after release of the results. Please note that all dates are subject to change.

Quarter	Date of release	Date of earnings call
Q2 2026	August 19, 2026	August 20, 2026
Q3 2026	November 11, 2026	November 12, 2026
Q4 2026	March 10, 2027	March 11, 2027

About Alvotech 

Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira^® (adalimumab), Stelara^® (ustekinumab), Simponi^® (golimumab), Eylea^® (aflibercept) and Prolia^®/Xgeva^® (denosumab). The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https://www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.

For more information, please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.

Forward Looking Statements

Certain statements in this communication may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech’s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech’s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.

Non IFRS Financial Measures

This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”) including, but not limited to, Adjusted Revenues, EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company’s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company’s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company’s financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

¹ Figures are adjusted to exclude items that are not indicative of our ongoing operating performance. See disclaimer on ‘Non IFRS Financial Measures’ at the end of this press release. As a foreign private issuer, Alvotech is not required to, and does not, prepare or file quarterly financial statements under IFRS or with the SEC. The financial information included in this Form 6-K reflects management’s current estimates and is presented for the purpose of providing an interim business update.

Exhibit 99.3

Alvotech

_____________________

Unaudited Condensed Consolidated Interim Financial Statements as

of 31 March 2026 and

for the three months ended 31 March 2026 and 2025

Table of Contents

Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss	F-2
Unaudited Condensed Consolidated Interim Statements of Financial Position	F-3 - F-4
Unaudited Condensed Consolidated Interim Statements of Cash Flows	F-5 - F-6
Unaudited Condensed Consolidated Interim Statements of Changes in Equity	F-7
Notes to the Unaudited Condensed Consolidated Interim Financial Statements	F-8 - F-25

F-1

Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss for the three months ended 31 March 2026 and 2025

USD in thousands, except for per share amounts		Notes		Three months ended 31 March 2026				Three months ended 31 March 2025
Product and service revenue		5			51,180				109,907
License and other revenue		5			54,685				22,858
Other income					80				41
Cost of product and service revenue					(46,087	)			(65,447	)
Research and development expenses					(24,511	)			(38,170	)
General and administrative expenses					(25,673	)			(18,607	)
Operating profit					9,674				10,582
Finance income		6			33,414				126,308
Finance costs		6			(40,807	)			(35,539	)
Exchange rate differences					(1,295	)			(7,930	)
Non-operating (loss) / profit					(8,688	)			82,839
Profit before taxes					986				93,421
Income tax benefit		7			44				16,259
Profit for the period					1,030				109,680
Other comprehensive (loss) / profit
Item that will be reclassified to profit or loss in subsequent periods:
Exchange rate differences on translation of foreign operations					(951	)			241
Total comprehensive profit					79				109,921
Profit per share
Basic profit for the period per share		8			0.00				0.39
Diluted profit for the period per share		8			0.00				0.35

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Interim Financial Statements.

F-2

Unaudited Condensed Consolidated Interim Statements of Financial Position as of 31 March 2026 and 31 December 2025

USD in thousands

Non-current assets		Notes		31 March 2026				31 December 2025
Property, plant and equipment		9			360,226				356,398
Right-of-use assets		10			135,001				138,294
Goodwill					12,514				12,835
Other intangible assets		11			119,593				81,834
Contract assets		5			130,033				122,934
Other long-term assets					14,957				8,578
Deferred tax assets		7			192,863				192,211
Total non-current assets					965,187				913,084
Current assets
Inventories		13			228,017				220,054
Trade receivables					47,820				69,740
Contract assets		5			58,386				64,440
Other current assets		14			57,261				46,984
Receivables from related parties		18			665				438
Cash and cash equivalents		12			63,832				172,359
Total current assets					455,981				574,015
Total assets					1,421,168				1,487,099

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Interim Financial Statements.

F-3

Unaudited Condensed Consolidated Interim Statements of Financial Position as of 31 March 2026 and 31 December 2025

USD in thousands

Equity		Notes		31 March 2026				31 December 2025
Share capital		15			2,930				2,929
Share premium		15			2,106,919				2,105,691
Other reserves					16,198				15,331
Translation reserve					401				1,352
Accumulated deficit					(2,408,760	)			(2,409,790	)
Total equity					(282,312	)			(284,487	)
Non-current liabilities
Borrowings		16			1,267,117				1,262,147
Derivative financial liabilities					21,763				53,994
Lease liabilities		10			134,524				137,999
Contract liabilities		5			13,128				5,500
Deferred tax liability		7			7,164				7,868
Total non-current liabilities					1,443,696				1,467,508
Current liabilities
Trade and other payables					97,865				126,124
Lease liabilities		10			13,126				12,078
Current maturities of borrowings		16			42,514				36,921
Liabilities to related parties		18			2,377				3,325
Contract liabilities		5			9,547				30,364
Taxes payable					2,048				1,041
Other current liabilities		19			92,307				94,225
Total current liabilities					259,784				304,078
Total liabilities					1,703,480				1,771,586
Total equity and liabilities					1,421,168				1,487,099

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Interim Financial Statements.

F-4

Unaudited Condensed Consolidated Interim Statements of Cash Flows for the three months ended 31 March 2026 and 2025

USD in thousands

Cash flows from operating activities		Notes		Three months ended 31 March 2026				Three months ended 31 March 2025
Profit for the period					1,030				109,680
Adjustments for non-cash items:
Depreciation, amortization and impairment					10,287				8,259
Change in inventory reserves		13			3,057				686
Share-based payments					2,344				1,308
Finance income		6			(33,414	)			(126,308	)
Finance costs		6			40,807				35,539
Exchange rate difference					1,295				7,930
Income tax benefit		7			(44	)			(16,259	)
Operating cash flow before movement in working capital					25,362				20,835
(Increase) in inventories		13			(11,020	)			(14,871	)
Decrease in trade receivables					21,920				9,028
(Increase) in receivables with related parties		18			(227	)			(60	)
(Increase) / decrease in contract assets		5			(1,953	)			18,498
(Increase) in other assets		14			(8,157	)			(3,705	)
(Decrease) / increase in trade and other payables					(34,339	)			3,808
(Decrease) in contract liabilities		5			(12,871	)			—
(Decrease) in liabilities with related parties		18			(948	)			(3,738	)
(Decrease) in other liabilities		19			(3,013	)			(12,410	)
Cash (used in) / from operations					(25,246	)			17,385
Interest received					136				25
Interest paid					(35,041	)			(4,831	)
Income tax paid					(278	)			(30	)
Net cash (used in) / provided by operating activities					(60,429	)			12,549
Cash flows from investing activities
Acquisition of property, plant and equipment		9			(7,142	)			(23,187	)
Acquisition of intangible assets		11			(39,053	)			(183	)
Proceeds from the sale in joint venture					—				2,975
Net cash used in investing activities					(46,195	)			(20,395	)

F-5

Cash flows from financing activities		Notes		Three months ended 31 March 2026				Three months ended 31 March 2025
Repayments of borrowings		16			(9,046	)			(3,563	)
Repayments of principal portion of lease liabilities		10			(3,163	)			(2,276	)
Proceeds from new borrowings		16			13,496				—
Transaction cost from new borrowings					(2,254	)			—
Net cash used in financing activities					(967	)			(5,839	)
(Decrease) in cash and cash equivalents		12			(107,591	)			(13,685	)
Cash and cash equivalents at the beginning of the year		12			172,359				51,428
Effect of movements in exchange rates on cash held					(936	)			801
Cash and cash equivalents at the end of the period		12			63,832				38,544

Supplemental cash flow disclosures (Note 21)

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Interim Financial Statements.

F-6

Unaudited Condensed Consolidated Interim Statements of Changes in Equity for the three months ended 31 March 2026 and 2025

USD in thousands

		Share capital				Share premium				Other reserves				Translation reserve				Accumulated deficit				Total equity
At 1 January 2025			2,826				2,007,058				17,272				(2,218	)			(2,437,709	)			(412,771	)
Profit for the period			—				—				—				—				109,680				109,680
Foreign currency translation differences			—				—				—				241				—				241
Total comprehensive profit			—				—				—				241				109,680				109,921
Recognition of share-based payments			—				—				1,249				—				—				1,249
Stock options recognised			—				—				81				—				—				81
Settlement of RSUs with shares			2				452				(1,221	)			—				—				(767	)
At 31 March 2025			2,828				2,007,510				17,381				(1,977	)			(2,328,029	)			(302,287	)
At 1 January 2026			2,929				2,105,691				15,331				1,352				(2,409,790	)			(284,487	)
Profit for the period			—				—				—				—				1,030				1,030
Foreign currency translation differences			—				—				—				(951	)			—				(951	)
Total comprehensive profit			—				—				—				(951	)			1,030				79
Recognition of share-based payments			—				—				2,261				—				—				2,261
Stock options recognised			—				—				91				—				—				91
Settlement of RSUs with shares			1				1,228				(1,485	)			—				—				(256	)
At 31 March 2026			2,930				2,106,919				16,198				401				(2,408,760	)			(282,312	)

The accompanying notes are an integral part of these Unaudited Condensed Consolidated Interim Financial Statements.

F-7

1. General information

Alvotech (the “Parent” or the “Company” or “Alvotech”) is a Luxembourg public limited company (société anonyme) incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273 Luxembourg, Grand Duchy of Luxembourg and is registered with the Luxembourg Trade and Companies’ Register under number B 258884. The Company was incorporated on 23 August 2021. These condensed consolidated interim financial statements were approved by the Group’s Board of Directors, and authorized for issue, on 8 June 2026.

The Company and its subsidiaries (collectively referred to as the “Group”) are a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide. The Group has commercialized a certain biosimilar product and has multiple biosimilar molecules.

1.2 Information about shareholders

Significant shareholders of the Company are Aztiq Pharma Partners S.à r.l. (Aztiq) and Alvogen Lux Holdings S.à r.l. (Alvogen), with 33.3% and 28.9% ownership interest as of 31 March 2026, respectively. The remaining 37.8% ownership interest is held by various entities, with no single shareholder holding more than 2.4% ownership interest as of 31 March 2026.

1.3 Going concern

The Group has primarily funded its operations with proceeds from the issuance of ordinary shares and the issuance of loans and borrowings to both related parties and third parties. Since its inception, the three months ended 31 March 2026 was the second period in which the Group generated profit, with a profit of $1.0 million for the three months ended 31 March 2026, compared to a profit of $109.7 million for three months ended 31 March 2025, and had an accumulated deficit of $2,408.8 million as of 31 March 2026 and $2,409.8 million as of 31 December 2025.

As of 31 March 2026, the Group had cash and cash equivalents of $63.8 million and current assets less current liabilities of $196.2 million.

During the three months ended 31 March 2026, the Group’s financial position and liquidity outlook were impacted by several developments (see Note 3 — Significant changes in the current reporting period for additional details).

In January 2026, the Group entered into a settlement and licensing agreement with Regeneron and Bayer relating to AVT06, providing increased visibility on commercialization and establishing launch timelines across key markets outside the United States, which is expected to support future revenue generation.

In February 2026, the Group further expanded its commercial platform through new supply and commercialization agreements with Sandoz covering Canada, Australia, and New Zealand. These agreements broaden the Group’s geographic footprint and are expected to contribute to future milestone and product revenues, subject to regulatory approvals and market uptake.

The Group also reported positive pivotal study results for AVT80 in February 2026, enabling progression toward regulatory submissions. While representing an important pipeline milestone, this development does not have an immediate impact on liquidity.

In February 2026, the Company issued 12,500,000 shares to a wholly owned subsidiary, classified as treasury shares. This transaction did not generate external cash proceeds but enhances flexibility to settle existing financial instruments, including convertible bonds and share-based obligations.

Additionally, in February 2026, the Board approved a further restructuring initiative. The Group expects to incur restructuring costs during 2026; however, these actions are intended to reduce the ongoing cost base and support improved future cash flows.

The Group expects to fund its activities through a combination of existing cash, projected cash generated from milestone collections and product revenues under commercial agreements, and financing arrangements available to the Group.

F-8

While several of the Group’s biosimilar programs have recently been launched and others are advancing through regulatory approval and commercialization, uncertainty remains regarding the timing and magnitude of future cash inflows. The Group continues to rely on the successful commercialization of its marketed products, including AVT02 (adalimumab) and AVT04 (ustekinumab), as well as the execution of upcoming launches, including AVT03 (denosumab), AVT05 (golimumab), and AVT06 (aflibercept), which has been further supported by the settlement agreement entered into in January 2026.

Although these developments, together with expanded commercial partnerships and ongoing cost optimization initiatives, improve the Group’s revenue visibility and operating outlook, the timing of cash flow generation remains subject to regulatory approvals, market access, and commercial performance. As a result, the Group may need to access additional financing in the future, which is dependent on market conditions and the availability of funding sources that are not entirely within the Group’s control. If sufficient funding is not available, management may be required to delay, scale back, or discontinue certain development or commercialization activities.

In conclusion, based on the existing cash on hand and projected future cash flows, management concluded that the Group has the ability to continue as a going concern for at least one year after the date that the unaudited condensed consolidated interim financial statements are issued. As such, the unaudited condensed consolidated interim financial statements have been prepared on a going concern basis.

2. Basis of preparation

The unaudited condensed consolidated interim financial statements of the Group as of and for the three months ended 31 March 2026 have been prepared in accordance and in compliance with International Accounting Standard 34 Interim Financial Reporting (IAS 34) as issued by the International Accounting Standards Board (IASB). Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS® Accounting Standards (IFRS) as issued by the IASB, have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Group’s audited annual consolidated financial statements for the year ended 31 December 2025, and accompanying notes, which have been prepared in accordance with IFRS as issued by the IASB and as adopted by the European Union (the “EU”).

The accounting policies and basis of preparation adopted in the preparation of these unaudited condensed consolidated interim financial statements are consistent with those followed in the preparation of the Group’s consolidated financial statements issued for the year ended 31 December 2025, except for the adoption of new and amended accounting standards effective as of 1 January 2026. The Group has not early adopted any other standards, interpretations or amendments that have been issued but are not yet effective. The unaudited condensed consolidated interim financial statements are presented in U.S. dollars and all values are rounded to the nearest thousand unless otherwise indicated.

In the opinion of the Group’s management, these unaudited condensed consolidated interim financial statements contain all normal recurring adjustments necessary to present fairly the financial position and results of operations of the Group for each of the periods presented. The condensed consolidated statement of financial position as of 31 December 2025 was derived from the consolidated financial statements at that date.

In preparing these unaudited condensed consolidated interim financial statements, management has made judgments and estimates that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. The significant judgments made by management in applying the Group’s accounting policies and the key sources of estimation uncertainty were the same as those described in the Group´s consolidated financial statements issued for the year ended 31 December 2025.

The estimates and associated assumptions are based on information available when the unaudited condensed consolidated interim financial statements are prepared, historical experience and other factors that are considered to be relevant. Judgments and assumptions involving key estimates are primarily made in relation to the measurement and recognition of revenue, the valuation of derivative financial liabilities, the valuation of deferred tax assets, and the purchase price allocation with respect to the asset acquisition. Actual results may differ from these estimates.

F-9

3. Significant changes in the current reporting period

The financial position and performance of the Group was impacted by the following events and transactions during the three months ended 31 March 2026:

On 29 January 2026, the Group announced that it had entered into a settlement and licensing agreement with Regeneron and Bayer regarding AVT06, its proposed biosimilar to Eylea (aflibercept), which is approved for marketing in the European Economic Area, United Kingdom and Japan. The agreement provides the Group with commercial certainty in global markets and forms part of the ongoing preparations for future regulatory submissions and market entry.The settlement agreement allows Alvotech and its commercial partners to market and sell the biosimilar as of 1 January 2026 in the United Kingdom and Canada, as well as in Japan (excluding the diabetic macular edema indication) starting 1 May 2026 in the European Economic Area and all other countries in the world (other than the U.S.), and from 1 November 2026 in Japan with all approved indications.

On 2 February 2026, the Group entered into new supply and commercialization agreements with Sandoz for Canada, Australia, and New Zealand. In Canada, the agreement covers one biosimilar candidate in ophthalmology supplied as a prefilled syringe for intravitreal injection. In Australia and New Zealand, the agreement encompasses three biosimilar candidates across immunology and gastroenterology, in multiple formulations. The agreement covers multiple biosimilar candidates and further expands the Group’s geographic commercial footprint.

On 5 February 2026, the Group announced positive top-line results from its pivotal pharmacokinetic study for AVT80, a proposed biosimilar to Entyvio (vedolizumab). The study met all primary endpoints, demonstrating pharmacokinetic similarity as well as comparable safety, tolerability, and immunogenicity profiles. These results enable the Group to progress toward regulatory submissions for both AVT16 and AVT80, the intravenous and subcutaneous biosimilar candidates, respectively.

On February 11, 2026, the Company issued 12,500,000 new shares, all of which were subscribed by its wholly-owned subsidiary Alvotech Manco ehf. and classified as treasury shares without voting or dividend rights. The increase in treasury shares was undertaken to restore the number of treasury shares available following settlement of shares lent under the stock-lending facility that supported investors’ hedging of the Convertible Bonds issued in December 2025 (refer to Note 16) and to ensure the Company maintains a sufficient pool of shares for outstanding financial commitments, including warrants, convertible instruments, and share-based compensation programs.

In February 2026, the Board approved an additional restructuring plan affecting several functions across the Group, with related employee notifications issued in early 2026. The Group expects to incur termination benefits and related restructuring costs in 2026 in connection with this plan.

4. New accounting standards

New Standards and Interpretations, which became effective as of 1 January 2026, did not have a material impact on our unaudited condensed consolidated interim financial statements.

F-10

5. Revenue

Disaggregated revenue

The following table summarizes the Group’s revenue from contracts with customers, disaggregated by the type of good or service and timing of transfer of control of such goods and services to customers during the three months ended 31 March 2026 and 2025:

		31 March
		2026				2025
Product and service revenue (point in time revenue recognition)			51,180				109,907
License revenue (point in time revenue recognition)			—				—
Performance revenue (point in time revenue recognition)			—				22,858
Development and other service revenue (over time revenue recognition)			54,685				—
			105,865				132,765

Performance revenue is disaggregated from license revenue as the Company reached significant performance milestones during the period in 2025.

Revenue from customers based on the geographic market in which the revenue is earned, which predominantly aligns with the rights conveyed to the Group’s customers pursuant to its out-license contracts, is as follows:

		31 March
		2026				2025
Europe			57,606				66,547
USA			34,531				63,334
Rest of World			13,728				2,884
			105,865				132,765

Contract assets and liabilities

A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below:

		Contract Assets				Contract Liabilities
31 December  2025			187,374				35,864
Contract asset additions			30,584				—
Amounts transferred to trade receivables			(28,555	)			—
Derecognition of contract liability			—				—
Customer prepayments			—				11,305
Revenue recognized			—				(24,101	)
Foreign currency adjustment			(984	)			(393	)
31 March  2026			188,419				22,675

F-11

The net increase in contract assets as of 31 March 2026 is due to the revenue recognized when the performance obligation has been met which is offset by transfer of amounts to trade receivables on the basis that the Group’s right to that consideration is no longer contingent on its performance. The net decrease in contract liabilities as of 31 March 2026 is due to revenue recognized when the performance obligation has been met which is offset by customer prepayments in advance of the Group's performance. As of 31 March 2026, $130.0 million and $58.4 million are recorded as non-current contract assets and current contract assets, respectively. Non-current contract assets will materialize over the next 2 to 4 years. As of 31 March 2026, $13.1 million and $9.5 million are recorded as non-current contract liabilities and current contract liabilities, respectively. Non-current contract liabilities will be recognized as revenue over the next 2 to 3 years as either services are rendered or contractual milestones are achieved, depending on the performance obligation to which the payment relates.

Remaining performance obligations

Due to the long-term nature of the Group’s out-license contracts, the Group’s obligations pursuant to such contracts represent partially unsatisfied performance obligations at the end of the period. The revenues under existing out-license contracts with original expected durations of more than one year are estimated to be $294.6 million. The Group expects to recognize the majority of these revenues over the next 5 years.

Out-license agreements

Teva Pharmaceutical Industries Ltd. (Teva)

In August 2020, the Group entered into an exclusive strategic agreement with Teva for the commercialization in the United States for five of the Group’s biosimilar product candidates. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas. Under this agreement, the Group will be responsible for the development, registration and supply of the biosimilars, while Teva will be exclusively commercializing the products in the United States pursuant to an intellectual property license granted by the Group to Teva. This agreement was subsequently amended in June 2021, February 2023, and July 2023, for the exclusive commercialization of additional biosimilar products in the United States.

In connection with the agreement, Teva made upfront payments of $40 million up to 31 March 2026. The Group also received $70.0 million in development milestones, $40.0 million in milestones related to the first commercial sale and other sales target through 31 March 2026, and is entitled to receive up to an additional $465 million in development and sales target milestones. Subject to some limitations, as consideration for supply of product the Group will receive 40% of the value of Teva’s net sales of the products.

STADA Arzneimittel AG (Stada)

In November 2019, the Group entered into an exclusive strategic agreement with Stada for the commercialization of six biosimilar products in all key European markets and selected markets outside Europe. The initial pipeline contains biosimilar candidates aimed at treating autoimmunity, oncology, ophthalmology and inflammatory conditions. Under this agreement, the Group will be responsible for the development, registration and supply of the biosimilars, while Stada will be exclusively commercializing the products in the relevant territories pursuant to an intellectual property license granted by the Group to Stada.

Three product agreements were terminated in May 2023, resulting in repayment of €17.4 million and reversion of rights to the Group. Subsequent amendments expanded Stada’s commercial rights for the remaining three biosimilars to additional territories.

In connection with the agreement, Stada made an upfront payment of $6.7 million up to 31 March 2026. The Group also received $73.4 million in development milestones, $25.5 million in milestones related to the first commercial sale and other sales target through 31 March 2026, and is entitled to receive up to an aggregate of $6.9 million in development and sales target milestones. The Group is also expected to receive a royalty of approximately 40% of the estimated net selling price from Stada’s and its affiliates’ commercialization of the contracted biosimilar products.

F-12

Advanz Pharma Holdings (Advanz Pharma)

In February 2023, the Group entered into an exclusive strategic agreement with Advanz Pharma for the commercialization of one biosimilar in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand. Under the agreement, the Group is responsible for development and supply, while Advanz Pharma handles registration and commercialization. The partnership was expanded in May 2023 to include five additional biosimilar products in Europe.

Further amendments in June 2024 and May 2025 extended the partnership to include five additional biosimilar products. Advanz Pharma holds exclusive commercialization rights in Europe, with semi-exclusive rights in Germany and France for two of the products.

In connection with the agreements, Advanz Pharma made upfront payments of $156.6 million up to 31 March 2026. The Group also received $61.2 million development milestones, $4.2 million in milestones related to the first commercial sale and other sales target through 31 March 2026. Additionally, the Group is eligible to receive up to an additional $534.7 million in development and sales target milestones. The Group is also expected to receive a royalty of 40% of the estimated net selling price from Advanz Pharma’s and its affiliates’ commercialization of the contracted biosimilar products.

Alvogen Inc. (Alvogen)

In December 2025, the Group entered into an exclusive strategic agreement with Alvogen for the commercialization of three biosimilar in United States. Under the agreement, the Group is responsible for development and supply, while Alvogen handles registration and commercialization.

In connection with the agreement, Alvogen made upfront payments of $15.0 million up to 31 March 2026. Additionally, the Group is eligible to receive up to an additional $195.0 million in development, regulatory and sales target milestones. The Group is also expected to receive a royalty of 40% of the estimated net selling price from Alvogen’s and its affiliates’ commercialization of the contracted biosimilar products. Alvogen is a related party to the Company (refer to Note 18 for further details).

6. Finance income and finance costs

Finance income earned for the three months ended 31 March 2026 and 2025 are as follows:

		31 March
		2026				2025
Changes in the fair value of derivatives (see Note 20)			32,231				125,609
Interest income from cash and cash equivalents			1,004				674
Other interest income			179				25
			33,414				126,308

Finance costs incurred for the three months ended 31 March 2026 and 2025 are as follows:

		31 March
		2026				2025
Interest on debt and borrowings			(34,660	)			(32,041	)
Interest on lease liabilities (see Note 10)			(2,650	)			(1,973	)
Amortization of deferred debt issue costs			(3,497	)			(1,525	)
			(40,807	)			(35,539	)

7. Income tax

The Group’s effective tax rate for the three months ended 31 March 2026 and 2025 was (4.5)% and (17.4)%, based on a tax benefit respectively. The effective tax rate for both periods is mainly influenced by the fair value adjustments of the derivative financial liabilities (refer to Note 20) which are not tax effected, non-deductible interest and losses incurred in Luxembourg for which no deferred tax asset is recognized and other permanent differences. The effective tax rate for both periods is effected by a favorable foreign exchange impact arising from the strengthening of the Icelandic krona against the U.S. dollar which increased the U.S. dollar value of tax loss carryforwards denominated in Icelandic krona.

F-13

Deferred tax assets have been recognized in relation to ordinary timing differences arising from amortization, depreciation, reserves, employee benefits other provisions and tax losses carried forward in the Group. The deferred tax assets on tax losses relates to tax losses arising in Iceland that management considers probable that future forecasted profit associated with product, license and other revenue will be available to offset the tax losses as of 31 March 2026. No deferred tax asset is recognized on tax losses arising in Luxembourg as their recoverability is unlikely to be realized.

As of 31 March 2026, the Group had $192.9 million in deferred tax assets and $192.2 million as of 31 December 2025.

8. Profit / (loss) per share

The calculation of basic profit per share for the three months ended 31 March 2026 and 2025 is as follows (in thousands, except for share and per share amounts):

		2026				2025
Earnings
Profit for the period			1,030				109,680
Number of shares
Weighted average number of ordinary shares outstanding			294,297,929				284,059,500
Basic profit per share			—				0.39

Diluted earnings per share is calculated to give effect to the potential dilutive effect that could occur if additional ordinary shares were assumed to be issued under securities or instruments that may entitle their holders to obtain ordinary shares in the future, which include share-based compensation awards (see Note 17—Share-based payments for additional details) and the OACB warrants (see Note 20 —Financial instruments for additional details). The number of additional shares for inclusion in the diluted earnings per share calculation was determined using the treasury stock method.

The calculation of diluted profit per share for the three months ended 31 March 2026 and 2025 is as follows (in thousands, except for share and per share amounts):

		2026				2025
Earnings
Profit for the period			1,030				109,680
After-tax impact of fair value adjustment OACB warrants			—				(8,443	)
Fully diluted profit for the period			1,030				101,237
Number of shares
Weighted average number of ordinary shares outstanding			294,297,929				284,059,500
Dilutive effect of share-based compensation			660,687				1,991,166
Dilutive effect of OACB warrants			—				274,817
Weighted average number of diluted ordinary shares outstanding			294,958,616				286,325,483
Diluted profit per share			—				0.35

F-14

9. Property, plant and equipment

During the three months ended 31 March 2026, the Group acquired items of property, plant and equipment with a cost of $10.3 million, primarily consisting of facility equipment. The Group recognized $6.0 million and $4.7 million of depreciation expense for the three months ended 31 March 2026 and 2025, respectively.

During the three months ended 31 March 2026 and 2025, the Group recognized no impairments of property, plant and equipment.

The Group pledged $360.2 million and $356.4 million of property, plant and equipment as collateral to secure borrowings with third parties as of 31 March 2026 and 31 December 2025, respectively.

10. Leases

The Group’s leased assets consist of facilities, fleet and equipment pursuant to both arrangements with third parties and related parties. The carrying amounts of the Group’s right-of-use assets and the movements during the three months ended 31 March 2026 are as follows:

		2026
Right-of-use assets
Balance at 1 January			138,294
Adjustments for indexed leases			3,579
New leases			259
Cancelled leases			(2,952	)
Depreciation			(3,784	)
Translation difference			(395	)
Balance at 31 March			135,001

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The Group’s lease liabilities and the movements during the three months ended 31 March 2026 are as follows:

		2026
Lease liabilities
Balance at 1 January			150,077
Adjustments for indexed leases			3,578
New leases			245
Cancelled leases			(3,257	)
Installment payments			(3,149	)
Foreign currency adjustment			333
Translation difference			(177	)
Balance at 31 March			147,650
Current liabilities			(13,126	)
Non-current liabilities			134,524

F-15

The amounts recognized in the unaudited condensed consolidated interim statements of profit or loss and other comprehensive income or loss during the three months ended 31 March 2026 and 2025 in relation to the Group’s lease arrangements are as follows:

		31 March
		2026				2025
Total depreciation expense from right-of-use assets			(3,784	)			(2,924	)
Interest expense on lease liabilities			(2,650	)			(1,973	)
Foreign currency difference on lease liability			(333	)			(5,886	)
Total amount recognized in profit and loss			(6,767	)			(10,783	)

The maturity analysis of undiscounted lease payments as of 31 March 2026 is as follows:

		2026
Less than one year			18,947
One to five years			69,892
Thereafter			101,057
			189,896

11. Other Intangible assets

During the three months ended 31 March 2026, intangible assets increased by $38.3 million, mainly in-process development. The Group recognized $0.5 million and $0.5 million of amortization expense for the three months ended 31 March 2026 and 2025, respectively.

During the three months ended 31 March 2026 and 2025, the Group recognized no impairments of intangible assets.

12. Cash and cash equivalents

Cash and cash equivalents include both cash in banks and on hand. Cash and cash equivalents as of 31 March 2026 and 31 December 2025 are as follows:

		31 March 2026				31 December 2025
Cash and cash equivalents denominated in US dollars			48,309				161,299
Cash and cash equivalents denominated in other currencies			15,523				11,060
			63,832				172,359

F-16

13. Inventories

The Group’s inventory balances as of 31 March 2026 and 31 December 2025 are as follows:

		31 March 2026				31 December 2025
Raw materials and supplies			100,491				102,158
Work in progress			136,278				124,330
Finished goods			2,122				1,383
Inventory reserves			(10,874	)			(7,817	)
Total Balance			228,017				220,054

The Group recognized $39.6 million and $54.8 million within cost of goods sold during the three months ended 31 March 2026 and 2025, respectively.

14. Other current assets

The composition of other current assets as of 31 March 2026 and 31 December 2025 is as follows:

		31 March 2026				31 December 2025
Value-added tax			22,940				17,924
Prepaid expenses			31,078				27,816
Other short-term receivables			3,243				1,244
			57,261				46,984

15. Share capital

Movements in the Group’s Ordinary shares, share capital and share premium during the three months ended 31 March 2026 are as follows (in thousands, except for share amounts):

		Ordinary Shares				Share capital				Share premium				Total
Balance at 1 January 2026			312,021,375				2,929				2,105,691				2,108,620
Settlement of RSUs with shares			131,789				1				1,228				1,229
Balance at 31 March 2026			312,153,164				2,930				2,106,919				2,109,849

No dividends were paid or declared during the three months ended 31 March 2026 and 2025.

F-17

16. Borrowings

The Group’s debt consists of interest-bearing borrowings from financial institutions and third parties. Outstanding borrowings, net of transaction costs and debt discounts, presented on the consolidated statements of financial position as current and non-current as of 31 March 2026 and 31 December 2025 are as follows:

		31 March 2026				31 December 2025
Senior Secured First Lien Term Loan Facility			1,031,822				1,031,565
2025 Convertible Bonds			69,938				68,367
Senior Term Loan Facility			97,117				96,719
Other borrowings			110,754				102,417
Total outstanding borrowings, net of debt issue costs			1,309,631				1,299,068
Less: current portion of borrowings			(42,514	)			(36,921	)
Total non-current borrowings			1,267,117				1,262,147

On 12 February 2026, the Group entered into a premium finance agreement with AFCO Premium Credit LLC for an amount of $1.6 million, in connection with the financing of insurance premiums. Per the terms of the agreement, this includes monthly installment payments with final maturity in December 2026. The agreement bears a fixed interest rate of 6.424%. As of 31 March 2026, the outstanding balance on the loan was $1.4 million.

In March 2026, the Group increased the loans related to the asset acquisition for the manufacturing facility in Reykjavik by $8.0 million through an additional borrowing with Landsbankinn hf., under substantially similar terms, including a variable interest rate of SOFR plus a margin of 4.05% and a maturity aligned with the existing facility in February 2030. The incremental borrowing is secured on the same collateral package as the existing Facility loans. As of 31 March 2026, the carrying amount of this incremental facility is $8 million.

The weighted-average interest rates of outstanding borrowings for the three months ended 31 March 2026 and the year ended 31 December 2025 are 9.42% and 9.58%, respectively.

Movements in the Group’s outstanding borrowings during the three months ended 31 March 2026 are as follows:

		2026
Borrowings, net at 1 January			1,299,068
Accretion/derecognition of borrowings discount			1,405
Proceeds from new borrowings			15,078
Repayments of borrowings			(9,046	)
Accrued interest			(80	)
Amortization of deferred debt issue costs			3,498
Foreign currency exchange difference			(292	)
Borrowings, net at 31 March			1,309,631

F-18

Contractual maturities of principal amounts on the Group’s outstanding borrowings as of 31 March 2026 are as follows:

		31 March 2026
Within one year			42,514
Within two years			123,593
Within three years			23,726
Within four years			1,082,932
Thereafter			116,982
			1,389,747

17. Share-based payments

On 1 December 2022, the Remuneration Committee approved and the Group granted RSUs to employees, executives, and directors. These RSUs entitle recipients to receive Ordinary Shares upon satisfying the applicable vesting conditions. The compensation expense for RSUs is based on the market price of the Ordinary Shares on the grant date and is expensed over the vesting period, which generally spans 1 to 4 years. Vesting generally includes a 1 year cliff, after which shares vest either monthly or annually, contingent upon the participant fulfilling a required service period. Movements in RSUs during the three months ended 31 March 2026 are as follows:

		2026
		RSUs				Weighted Average Fair Value
Outstanding at 1 January			1,756,072			$	8.65
New grants during the period			1,637,555			$	4.58
Forfeited during the period			(219,500	)		$	9.64
Vested during the period			(550,420	)		$	6.47
Outstanding at 31 March			2,623,707			$	6.49

The Group recognized $2.3 million and $1.3 million of share-based payment expense during the three months ended 31 March 2026 and 2025, respectively, as follows:

		2026				2025
Cost of product revenue			62				542
Research and development expenses			342				257
General and administrative expenses			1,940				509
			2,344				1,308

F-19

18. Related parties

Related party transactions as of 31 March 2026 are as follows:

		Purchases / interest				Sold service				Receivables				Payables/ borrowings
Alvogen Lux Holdings S.à r.l. – Sister company (a)			1,472				—				—				1,472
Aztiq Consulting ehf. – Sister company			3				—				5				1
Flóki-Art ehf. - Sister company			—				—				—				414
Alvogen UK - Sister company			54				—				—				54
Alvogen Finance B.V. - Sister Company			731				—				—				—
Alvogen Inc.			—				—				—				656
Klettagarðar 6 ehf.  - Sister company (b)			333				222				4,306				2,941
Flóki Invest ehf - Sister company			172				—				—				71
Alvogen Spain SL			—				—				—				15
Norwich Clinical Services Ltd			265				—				—				105
Hlíðarvegur 20 ehf.			10				—				—				—
Fasteignafélagið Eyjólfur ehf - Sister company			2,869				—				—				96,479
Flóki fasteignir ehf. - Sister company			970				—				—				13,552
			6,879				222				4,311				115,760

(a) The full amount of purchased service relates to royalty expenses.

(b) The receivable is classified within Other long-term assets in the Unaudited Condensed Consolidated Interim Statement of Financial Position

F-20

Related party transactions for the three months ended 31 March 2025 and as of 31 December 2025 are as follows:

		31 March 2025								31 December 2025
		Purchased service / interest				Sold service				Receivables				Payables/ borrowings
Alvogen Lux Holdings S.à r.l. – Sister company			3,108				—				—				—
ATP Holdings ehf. - Sister company			—				—				—				125
Aztiq Consulting ehf. – Sister company			105				28				5				—
Flóki-Art ehf. - Sister company			36				—				—				430
Alvogen Iceland ehf.  - Sister company			5				—				—				—
Alvogen ehf.  - Sister company			—				22				—				—
Alvogen UK - Sister company			54				—				—				28
Alvogen Finance B.V. - Sister Company			296				—				—				—
Alvogen Inc. - Sister company			3				3				—				656
Adalvo Limited - Sister company			10				48				—				—
Klettagarðar 6 ehf.  - Sister company			—				—				4,037				2,923
L41 ehf. - Sister company			14				—				—				6
Flóki Invest ehf - Sister company			196				—				—				276
Alvogen Spain SL - Sister company			—				—				—				16
Norwich Clinical Services Ltd - Sister company			218				—				—				605
Hliðarvegur 20 ehf.			14				—				—				—
Fasteignafélagið Eyjólfur ehf - Sister company			2,878				—				—				96,304
Flóki fasteignir ehf. - Sister company			497				—				—				15,838
			7,434				101				4,042				117,207

F-21

19. Other current liabilities

The composition of other current liabilities as of 31 March 2026 and 31 December 2025 is as follows:

		31 March 2026				31 December 2025
Unpaid salary and salary related expenses			14,363				9,866
Accrued interest			20,680				19,860
Accrued vacation leave			9,674				9,337
Accrued commercial fees			24,718				24,718
Accrued royalties			9,955				10,933
Accrued other expenses			12,917				19,511
			92,307				94,225

Change in Accrued other expenses as of 31 March 2026 is mainly driven by a decrease of $3.5 million associated with the collaboration and license agreement with Dr. Reddy's and VAT liabilities by $1.5 million. The remainder of the balance is composed of recurring liabilities.

20. Financial instruments

Accounting classification and carrying amounts

It is management’s estimate that the carrying amounts of financial assets and financial liabilities carried at amortized cost approximate their fair value, with the exception of the 2025 Convertible Bonds and the Senior Secured First Lien Term Loan Facility.

Material differences between the fair values and carrying amounts of these borrowings are identified as follows:

		31 March 2026
		Carrying Amount				Fair Value
Senior Secured First Lien Term Loan Facility			1,031,822				1,076,312
2025 Convertible Bonds			69,938				68,685
			1,101,760				1,144,997

		31 December 2025
		Carrying Amount				Fair Value
Senior Secured First Lien Term Loan Facility			1,031,565				1,108,552
2025 Convertible Bonds			68,367				72,765
			1,099,932				1,181,317

F-22

Fair value measurements

The following tables illustrate the fair value measurement hierarchy of the Group’s financial instruments measured at fair value on a recurring basis as of 31 March 2026 and 31 December 2025:

		31 March 2026
		Level 1				Level 2				Level 3				Total
Conversion Feature			—				—				16,881				16,881
Predecessor Earn Out Shares			—				1,800				—				1,800
OACB Warrants			3,082				—				—				3,082
			3,082				1,800				16,881				21,763

		31 December 2025
		Level 1				Level 2				Level 3				Total
Conversion Feature			—				—				38,732				38,732
Predecessor Earn Out Shares			—				8,800				—				8,800
OACB Warrants			6,462				—				—				6,462
			6,462				8,800				38,732				53,994

The Group did not recognize any transfer of assets or liabilities between levels of the fair value hierarchy during the three months ended 31 March 2026.

Conversion Feature

The Conversion Feature had a fair value of $16.9 million as of 31 March 2026, resulting in $21.9 million of finance costs for the year ended 31 March 2026.

The fair value of the Conversion Feature is determined using a binomial option-pricing model that incorporates both observable market inputs and significant unobservable inputs.

The following table presents the assumptions and inputs that were used for the model in valuing the Conversion Feature:

		31 March 2026				31 December 2025
Share price		$	3.43			$	5.13
Volatility rate			34.7	%			30.7	%
Risk-free rate			18.7	%			16.2	%

F-23

Predecessor Earn Out Shares

The Predecessor Earn Out Shares had a fair value of $1.8 million as of 31 March 2026, resulting in $7.0 million of finance income for the three months ended 31 March 2026.

The fair value of the Predecessor Earn Out Shares was determined using Monte Carlo analysis that incorporated inputs and assumptions as further described below. The inputs and assumptions associated with the valuation of the instruments are determined based on all relevant internal and external information available and are reviewed and reassessed at each reporting date.

The following table presents the assumptions and inputs that were used for the model in valuing the Predecessor Earn Out Shares:

		31 March 2026				31 December 2025
Number of shares			19,165,000				19,165,000
Share price		$	3.43			$	5.13
Volatility rate			67.0	%			60.0	%
Risk-free rate			3.7	%			3.5	%

OACB Warrants

The OACB warrants had a fair value of $3.1 million as of 31 March 2026. The fair value of the warrants was derived from the publicly quoted trading price at the valuation date. The change in fair value of the OACB Warrants resulted in $3.4 million of finance income for the three months ended 31 March 2026.

21. Supplemental cash flow information

Supplement cash flow information for the three months ended 31 March 2026 and 2025 is included below:

		31 March
Non-cash investing and financing activities		2026				2025
Acquisition of property, plant and equipment in trade payables and other current liabilities			7,283				3,824
Acquisition of intangibles in trade payables and other current liabilities			14,966				1,207
Right-of-use assets obtained through new leases			259				3,074
Settlement of RSUs with shares			256				767
Settlement of trade payables through financing			1,582				—

F-24

22. Subsequent events

The Group evaluated subsequent events through 8 June 2026, the date that the unaudited condensed consolidated interim financial statements were available to be issued.

On 11 May 2026, Alvotech announced that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP surveillance inspection of the company’s manufacturing facility in Reykjavik, Iceland. At the conclusion of the inspection on 8 May 2026, the FDA issued a Form 483. The Company has stated that the observations are addressable and do not indicate material concerns with the site or its operations. On 4 June 2026, the Company announced the resubmission of Biologics License Applications (BLAs) to the FDA for AVT05 and AVT06 following the completion of the required data package and responses to the inspection observations. These applications relate to proposed biosimilars to Simponi®/Simponi Aria® and Eylea®, respectively. The timing and outcome of the FDA review process remain subject to regulatory review. Alvotech continues to expect FDA approval for the relevant BLAs during 2026.

On 8 June 2026, the Company announced that the FDA had accepted for review a BLA for AVT16, a proposed interchangeable biosimilar to Entyvio®. The timing and outcome of the FDA review process for this application remain subject to regulatory review. AVT16 is among Alvotech’s disclosed biosimilar candidates in immunology and form part of the company’s broader pipeline of biosimilar candidates aimed at expanding access to biologic medicines in major therapeutic areas. The BLA submission is supported by a comprehensive data package, including analytical, pharmacokinetic, and immunogenicity data generated to support the demonstration of biosimilarity between AVT16 and the reference product.

F-25

FAQ

How did Alvotech (ALVO) perform financially in Q1 2026?

Alvotech generated $105.9 million in total revenues in Q1 2026, down from $132.8 million a year earlier. Adjusted EBITDA was $24.4 million with a 57% gross margin, and reported profit reached $1.0 million, supported by significant finance income.

What is Alvotech’s 2026 outlook for revenue and Adjusted EBITDA?

Management expects 2026 total revenues of $650–$700 million and Adjusted EBITDA of $180–$220 million. The lower end of the revenue range assumes no contributions from new U.S. launches, so delivery depends on biosimilar uptake, milestones, and regulatory approvals across the portfolio.

What did the FDA decide about Alvotech’s AVT16 biosimilar?

The FDA has accepted for review Alvotech’s Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio. The company expects a review period of up to six months from submission, with development and manufacturing by Alvotech and U.S. commercialization by Teva.

What is Alvotech’s cash and debt position as of March 31, 2026?

Alvotech held $63.8 million in cash and cash equivalents at March 31, 2026. Outstanding borrowings totaled about $1.31 billion, mainly from term loans and 2025 convertible bonds, highlighting significant leverage and the importance of future cash generation and refinancing access.

How strong was Alvotech’s operating cash flow in Q1 2026?

Operating activities used $60.4 million of cash in Q1 2026, compared with inflows in the prior year period. The outflow reflected working capital movements, interest payments and ongoing investments in inventory and operations during facility improvements, contributing to the decline in cash balances.

Which key partnerships and agreements support Alvotech’s future revenues?

Alvotech has exclusive commercialization agreements with Teva, Stada, Advanz Pharma and Alvogen, alongside a settlement and licensing deal with Regeneron and Bayer on AVT06. These include substantial potential milestones, royalties around 40% of net selling price, and broadened geographic coverage.

Filing Exhibits & Attachments

3 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 8.8 KB
• EX-99.2 EXHIBIT 99.2 15.5 KB
• EX-99.3 EXHIBIT 99.3 372.3 KB